C4 Therapeutics Statistics
Total Valuation
C4 Therapeutics has a market cap or net worth of $114.29 million. The enterprise value is -$87.21 million.
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
C4 Therapeutics has 70.99 million shares outstanding. The number of shares has increased by 39.75% in one year.
| Current Share Class | 70.99M |
| Shares Outstanding | 70.99M |
| Shares Change (YoY) | +39.75% |
| Shares Change (QoQ) | +1.41% |
| Owned by Insiders (%) | 2.76% |
| Owned by Institutions (%) | 69.21% |
| Float | 47.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.14 |
| Forward PS | 6.57 |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.71, with a Debt / Equity ratio of 0.30.
| Current Ratio | 5.71 |
| Quick Ratio | 5.49 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.58% and return on invested capital (ROIC) is -24.46%.
| Return on Equity (ROE) | -45.58% |
| Return on Assets (ROA) | -20.17% |
| Return on Invested Capital (ROIC) | -24.46% |
| Return on Capital Employed (ROCE) | -38.49% |
| Revenue Per Employee | $323,491 |
| Profits Per Employee | -$957,418 |
| Employee Count | 110 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, C4 Therapeutics has paid $131,000 in taxes.
| Income Tax | 131,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.31% in the last 52 weeks. The beta is 3.12, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 3.12 |
| 52-Week Price Change | -76.31% |
| 50-Day Moving Average | 2.09 |
| 200-Day Moving Average | 4.43 |
| Relative Strength Index (RSI) | 49.30 |
| Average Volume (20 Days) | 1,337,336 |
Short Selling Information
The latest short interest is 7.76 million, so 10.93% of the outstanding shares have been sold short.
| Short Interest | 7.76M |
| Short Previous Month | 8.17M |
| Short % of Shares Out | 10.93% |
| Short % of Float | 16.43% |
| Short Ratio (days to cover) | 8.67 |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of $35.58 million and -$105.32 million in losses. Loss per share was -$1.52.
| Revenue | 35.58M |
| Gross Profit | -75.05M |
| Operating Income | -117.18M |
| Pretax Income | -106.59M |
| Net Income | -105.32M |
| EBITDA | -115.36M |
| EBIT | -117.18M |
| Loss Per Share | -$1.52 |
Full Income StatementBalance Sheet
The company has $244.90 million in cash and $65.76 million in debt, giving a net cash position of $201.51 million or $2.84 per share.
| Cash & Cash Equivalents | 244.90M |
| Total Debt | 65.76M |
| Net Cash | 201.51M |
| Net Cash Per Share | $2.84 |
| Equity (Book Value) | 215.99M |
| Book Value Per Share | 3.06 |
| Working Capital | 212.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$65.16 million and capital expenditures -$180,000, giving a free cash flow of -$65.34 million.
| Operating Cash Flow | -65.16M |
| Capital Expenditures | -180,000 |
| Free Cash Flow | -65.34M |
| FCF Per Share | -$0.92 |
Full Cash Flow StatementMargins
Gross margin is -210.92%, with operating and profit margins of -329.30% and -295.96%.
| Gross Margin | -210.92% |
| Operating Margin | -329.30% |
| Pretax Margin | -295.60% |
| Profit Margin | -295.96% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
C4 Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -39.75% |
| Shareholder Yield | -39.75% |
| Earnings Yield | -92.15% |
| FCF Yield | -57.17% |
Analyst Forecast
The average price target for C4 Therapeutics is $12.50, which is 669.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.50 |
| Price Target Difference | 669.23% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 126.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
C4 Therapeutics has an Altman Z-Score of -0.92 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.92 |
| Piotroski F-Score | 3 |